Chromane PET Radioligands for mGluR2 Brain Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PET tracers for metabotropic glutamate receptor 2 (mGluR2) suffer from poor brain uptake and insufficient heterogeneity, leading to inadequate imaging and diagnostic capabilities for neurological and psychiatric disorders.
Innovation Solution
Development of chromane and isochromane negative allosteric modulators (NAMs) as PET radioligands, specifically compounds like 5-(2-fluoro-4-([11C]-methoxy)phenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-7-carboxamide, which exhibit excellent brain permeability and heterogeneity, allowing for effective imaging of mGluR2 receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If previous mGluR2 NAM radioligands were used, then they could bind to mGluR2 receptors, but they exhibited poor brain uptake due to being substrates of transporter proteins on the blood-brain barrier
Solution Approach 1:
The patent modifies the chemical structure of mGluR2 NAM radioligands by changing parameters such as introducing specific substituent groups (e.g., fluorine atoms at particular positions, methoxy groups) and adjusting molecular weight and lipophilicity. These parameter changes enable the radioligands to evade recognition by P-gp efflux transporters while maintaining high affinity binding to mGluR2 receptors, thereby achieving excellent brain uptake and retention.
2Measurement precision
If previous mGluR2 NAM radioligands were used, then they could image mGluR2 distribution, but they showed insufficient brain heterogeneity
Solution Approach 1:
The patent designs radioligands with specific local chemical features (such as fluorine substitution at positions 2 or 4 of the phenyl ring, and specific substitutions on the pyridine ring) that enhance selective accumulation in brain regions with high mGluR2 density. This local quality optimization allows the radioligands to differentiate between various brain regions, providing superior heterogeneity information for imaging studies.
3Object-affected harmful factors
If chromane and isochromane NAM structures were developed as PET radioligands, then brain permeability and heterogeneity were improved, but synthesis and radiolabeling complexity increased
Solution Approach 1:
The patent employs preliminary action by pre-synthesizing and characterizing non-radioactive chromane and isochromane NAM compounds with optimized structures before radiolabeling. This allows for thorough evaluation of binding affinity, selectivity, and metabolic stability upfront, ensuring that only the most promising candidates proceed to radiolabeling. The pre-optimized structures facilitate more straightforward radiosynthesis with high specific activity and purity.
Solution Approach 2:
The patent uses stable intermediate compounds (such as boronic acid derivatives, stannane compounds, or halogenated precursors) that can be readily radiolabeled with carbon-11 or fluorine-18. These intermediaries serve as mediators between the complex chromane/isochromane core structure and the radioactive label, simplifying the overall synthesis pathway while maintaining the desired pharmacological properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed PET radioligands provide clear brain radioactivity distribution and metabolic insights, enabling accurate diagnosis and monitoring of mGluR2-related disorders, overcoming the limitations of previous tracers.
Implementation Method 1
5-(2-fluoro-4-([11C]-methoxy)phenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-7-carboxamide
Implementation Method 2
positron emission tomography (PET) radioligands to image metabotropic glutamate receptor 2 (mGluR2)
Data Source
AI summary
The present application provides radioisotope-containing compounds that are, e.g., mGluR2 modulators. Methods of imaging brain of a patient, as well as methods of diagnosing and monitoring treatment of psychiatric or neurological disorders in which mGluR2 is implicated, are also disclosed.